<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Both in vitro and in vivo studies indicate that <z:chebi fb="0" ids="6801">metformin</z:chebi> inhibits <z:e sem="disease" ids="C1516170" disease_type="Neoplastic Process" abbrv="">cancer cell growth</z:e> and reduces <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk </plain></SENT>
<SENT sid="1" pm="."><plain>Recent epidemiological studies suggest that <z:chebi fb="0" ids="6801">metformin</z:chebi> therapy may reduce the risks of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and overall <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> mortality among patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>However, data on its effect on <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> are limited and inconsistent </plain></SENT>
<SENT sid="3" pm="."><plain>We therefore pooled data currently available to examine the association between <z:chebi fb="0" ids="6801">metformin</z:chebi> therapy and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> among patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>RESEARCH DESIGN AND METHODS: The PubMed and SciVerse Scopus databases were searched to identify studies that examined the effect of <z:chebi fb="0" ids="6801">metformin</z:chebi> therapy on <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> among patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Summary effect estimates were derived using a random-effects meta-analysis model </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The analysis included five studies comprising 108,161 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> treatment was associated with a significantly lower risk of colorectal <z:hpo ids='HP_0002664'>neoplasm</z:hpo> (relative risk [RR] 0.63 [95% CI 0.50-0.79]; P &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>After exclusion of one study that investigated colorectal <z:mpath ids='MPATH_270'>adenoma</z:mpath>, the remaining four studies comprised 107,961 diabetic patients and 589 incident <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cases during follow-up </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> treatment was associated with a significantly lower risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (0.63 [0.47-0.84]; P = 0.002) </plain></SENT>
<SENT sid="10" pm="."><plain>There was no evidence for the presence of significant <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> between the five studies (Q = 4.86, P = 0.30; I(2) = 18%) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: From observational studies, <z:chebi fb="0" ids="6801">metformin</z:chebi> therapy appears to be associated with a significantly lower risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="12" pm="."><plain>Further investigation is warranted </plain></SENT>
</text></document>